2021. Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s52. DOI:https://doi.org/10.25251/skin.5.supp.52.